Warning message

  • This article was published in October 2017. The information may be out of date. Please check our epilepsy information or our site A-Z.
  • This article was published in September 2017. The information may be out of date. Please check our epilepsy information or our site A-Z.
  • This article was published in July 2017. The information may be out of date. Please check our epilepsy information or our site A-Z.
  • This article was published in March 2017. The information may be out of date. Please check our epilepsy information or our site A-Z.

Stories about EMA

Almost one-fifth of women taking sodium valproate for epilepsy still not aware of risks in pregnancy, survey shows

22 Sep 2017

Almost one-fifth (18%) of women taking the epilepsy medicine sodium valproate don’t know the risks this medicine can pose during pregnancy, according to the results of a new survey.

More than a quarter (28%) of the women currently taking sodium valproate said in the survey that they had not been informed of the risks of this medicine in pregnancy.

EMA public hearing on valproate-based medicines open for applications from EU citizens

14 Jul 2017

The European Medicines Agency (EMA) is holding a public hearing on medicines containing valproate on 26 September 2017 at its London offices.

The EMA assesses and oversees the safety of medicines in the EU. The announced public hearing is part of the EMA’s review into the use of valproate-based medicines in women who are pregnant or of childbearing age.

Subscribe to EMA